Diana O Perkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2105749/publications.pdf

Version: 2024-02-01

34016 9073 22,269 165 52 144 citations h-index g-index papers 166 166 166 15369 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes. Psychological Medicine, 2023, 53, 3644-3651.	2.7	5
2	North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophrenia Research, 2022, 243, 262-267.	1.1	39
3	Life Event Stress and Reduced Cortical Thickness in Youth at Clinical High Risk for Psychosis and Healthy Control Subjects. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 171-179.	1.1	2
4	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 111-121.	2.3	15
5	Individualized Prediction of Prodromal Symptom Remission for Youth at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 395-404.	2.3	7
6	Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis. Schizophrenia Research: Cognition, 2022, 27, 100225.	0.7	0
7	Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 1379-1388.	1.6	4
8	The associations between area-level residential instability and gray matter volumes from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2022, 241, 1-9.	1.1	8
9	Longitudinal impact of trauma in the North American Prodrome Longitudinal Studyâ€3. Microbial Biotechnology, 2022, 16, 1211-1216.	0.9	O
10	A greedy regression algorithm with coarse weights offers novel advantages. Scientific Reports, 2022, 12, 5440.	1.6	0
11	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
12	The use of diary methods to evaluate daily experiences in first-episode psychosis. Psychiatry Research, 2022, 312, 114548.	1.7	3
13	Family history of psychosis in youth at clinical high risk: A replication study. Psychiatry Research, 2022, 311, 114480.	1.7	3
14	Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis. JAMA Psychiatry, 2022, 79, 780.	6.0	21
15	The Association Between Neighborhood Poverty and Hippocampal Volume Among Individuals at Clinical High-Risk for Psychosis: The Moderating Role of Social Engagement. Schizophrenia Bulletin, 2022, 48, 1032-1042.	2.3	9
16	Cross-paradigm connectivity: reliability, stability, and utility. Brain Imaging and Behavior, 2021, 15, 614-629.	1.1	7
17	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 2021, 227, 10-17.	1.1	28
18	Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. Microbial Biotechnology, 2021, 15, 96-103.	0.9	9

#	Article	IF	Citations
19	Depression: An actionable outcome for those at clinical high-risk. Schizophrenia Research, 2021, 227, 38-43.	1.1	7
20	Social decline in the psychosis prodrome: Predictor potential and heterogeneity of outcome. Schizophrenia Research, 2021, 227, 44-51.	1.1	12
21	Concordance and factor structure of subthreshold positive symptoms in youth at clinical high risk for psychosis. Schizophrenia Research, 2021, 227, 72-77.	1.1	4
22	Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis. Schizophrenia Research, 2021, 227, 95-100.	1.1	17
23	Discriminatory experiences predict neuroanatomical changes and anxiety among healthy individuals and those at clinical high risk for psychosis. NeuroImage: Clinical, 2021, 31, 102757.	1.4	8
24	Abnormally Large Baseline P300 Amplitude Is Associated With Conversion to Psychosis in Clinical High Risk Individuals With a History of Autism: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 591127.	1.3	10
25	Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study. Schizophrenia Research, 2021, 230, 26-37.	1.1	4
26	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	0.7	32
27	Enhancing stress reactivity and wellbeing in early schizophrenia: A randomized controlled trial of Integrated Coping Awareness Therapy (I-CAT). Schizophrenia Research, 2021, 235, 91-101.	1.1	5
28	Clinician Recognition of First Episode Psychosis. Journal of Adolescent Health, 2021, 69, 457-464.	1.2	3
29	Anxiety in youth at clinical high-risk for psychosis: A two-year follow-up. Schizophrenia Research, 2021, 236, 87-88.	1.1	1
30	The association between migrant status and transition in an ultra-high risk for psychosis population. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 943-952.	1.6	5
31	Genetic and clinical analyses of psychosis spectrum symptoms in a large multiethnic youth cohort reveal significant link with ADHD. Translational Psychiatry, 2021, 11, 80.	2.4	11
32	Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2021, 238, 137-144.	1.1	7
33	Depression Predicts Global Functional Outcomes in Individuals at Clinical High Risk for Psychosis. Psychiatric Research and Clinical Practice, 2021, 3, 163-171.	1.3	4
34	Progressive reconfiguration of resting-state brain networks as psychosis develops: Preliminary results from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2020, 226, 30-37.	1.1	36
35	Stress perception following childhood adversity: Unique associations with adversity type and sex. Development and Psychopathology, 2020, 32, 343-356.	1.4	25
36	Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains. American Journal of Psychiatry, 2020, 177, 164-171.	4.0	34

3

#	Article	IF	CITATIONS
37	Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Molecular Psychiatry, 2020, 25, 2455-2467.	4.1	82
38	Common Data Elements for National Institute of Mental Health–Funded Translational Early Psychosis Research. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 10-22.	1.1	2
39	Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk. American Journal of Psychiatry, 2020, 177, 155-163.	4.0	90
40	Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophrenia Research, 2020, 216, 184-191.	1.1	22
41	Duration of the psychosis prodrome. Schizophrenia Research, 2020, 216, 443-449.	1.1	16
42	Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study. Clinical Neurophysiology, 2020, 131, 2899-2909.	0.7	6
43	Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort. Psychoneuroendocrinology, 2020, 115, 104649.	1.3	21
44	Potential Roles of Redox Dysregulation in the Development of Schizophrenia. Biological Psychiatry, 2020, 88, 326-336.	0.7	62
45	Stability of mismatch negativity eventâ€related potentials in a multisite study. International Journal of Methods in Psychiatric Research, 2020, 29, e1819.	1.1	10
46	Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis Journal of Abnormal Psychology, 2020, 129, 599-611.	2.0	15
47	Neurocognitive profiles in the prodrome to psychosis in NAPLS-1. Schizophrenia Research, 2019, 204, 311-319.	1.1	30
48	Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. JAMA Psychiatry, 2019, 76, 1187.	6.0	59
49	Recommendations and Challenges of the Clinical Services Panel of the PhenX Early Psychosis Working Group. Psychiatric Services, 2019, 70, 514-517.	1.1	7
50	Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. Psychiatry Research, 2019, 282, 112492.	1.7	24
51	Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. NeuroImage: Clinical, 2019, 23, 101862.	1.4	48
52	Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis. Schizophrenia Research, 2019, 213, 48-55.	1.1	21
53	The Early Psychosis Screener for Internet (EPSI)-SR: Predicting 12†month psychotic conversion using machine learning. Schizophrenia Research, 2019, 208, 390-396.	1.1	13
54	Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study. Schizophrenia Research, 2019, 208, 41-43.	1.1	15

#	Article	IF	CITATIONS
55	Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care. Journal of Clinical Psychiatry, 2019, 80, .	1.1	7
56	Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. Psychological Medicine, 2019, 49, 1670-1677.	2.7	74
57	Altered Brain Activation During Memory Retrieval Precedes and Predicts Conversion to Psychosis in Individuals at Clinical High Risk. Schizophrenia Bulletin, 2019, 45, 924-933.	2.3	14
58	Contribution of Rare Copy Number Variants toÂBipolar Disorder Risk Is Limited to Schizoaffective Cases. Biological Psychiatry, 2019, 86, 110-119.	0.7	45
59	The Global Functioning: Social and Role Scalesâ€"Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2019, 45, 763-772.	2.3	55
60	Tobacco use and psychosis risk in persons at clinical high risk. Microbial Biotechnology, 2019, 13, 1173-1181.	0.9	11
61	Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain, Behavior, and Immunity, 2019, 76, 268-274.	2.0	48
62	Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. Schizophrenia Research, 2019, 204, 96-103.	1.1	31
63	The role of a family history of psychosis for youth at clinical high risk of psychosis. Microbial Biotechnology, 2019, 13, 251-256.	0.9	10
64	Changes in symptom content from a clinical highâ€risk state to conversion to psychosis. Microbial Biotechnology, 2019, 13, 257-263.	0.9	7
65	Toward Leveraging Human Connectomic Data in Large Consortia: Generalizability of fMRI-Based Brain Graphs Across Sites, Sessions, and Paradigms. Cerebral Cortex, 2019, 29, 1263-1279.	1.6	55
66	Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia. Journal of Clinical Psychiatry, 2019, 80, .	1.1	1
67	The Early Psychosis Screener (EPS): Quantitative validation against the SIPS using machine learning. Schizophrenia Research, 2018, 197, 516-521.	1.1	11
68	Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. Schizophrenia Bulletin, 2018, 44, 254-263.	2.3	51
69	Latent class cluster analysis of symptom ratings identifies distinct subgroups within the clinical high risk for psychosis syndrome. Schizophrenia Research, 2018, 197, 522-530.	1.1	22
70	The Early Psychosis Screener (EPS): Item development and qualitative validation. Schizophrenia Research, 2018, 197, 504-508.	1.1	8
71	Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. Journal of Clinical Child and Adolescent Psychology, 2018, 47, 69-78.	2.2	17
72	Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophrenia Research, 2018, 192, 357-363.	1.1	45

#	Article	IF	Citations
73	Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. Schizophrenia Bulletin, 2018, 44, 286-296.	2.3	28
74	Exploration of clinical high-risk dropouts. Schizophrenia Research, 2018, 195, 579-580.	1.1	15
75	Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. Nature Communications, 2018, 9, 3836.	5.8	156
76	Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at Clinically High Risk. JAMA Psychiatry, 2018, 75, 960.	6.0	114
77	Enhancing stress reactivity and wellbeing in early schizophrenia: A pilot study of individual coping awareness therapy (I-CAT). Schizophrenia Research, 2018, 201, 413-414.	1.1	8
78	Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study. Schizophrenia Research, 2018, 201, 130-136.	1.1	13
79	Networks of blood proteins in the neuroimmunology of schizophrenia. Translational Psychiatry, 2018, 8, 112.	2.4	16
80	Anxiety in youth at clinical high risk for psychosis. Microbial Biotechnology, 2017, 11, 480-487.	0.9	56
81	Ventricular enlargement and progressive reduction of cortical gray matter are linked in prodromal youth who develop psychosis. Schizophrenia Research, 2017, 189, 169-174.	1.1	32
82	The Role of microRNA Expression in Cortical Development During Conversion to Psychosis. Neuropsychopharmacology, 2017, 42, 2188-2195.	2.8	12
83	Multisite reliability of MR-based functional connectivity. Neurolmage, 2017, 146, 959-970.	2.1	140
84	Comorbid diagnoses for youth at clinical high risk of psychosis. Schizophrenia Research, 2017, 190, 90-95.	1.1	95
85	Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. Psychiatry Research, 2017, 258, 462-468.	1.7	6
86	Evidence that endogenous formaldehyde produces immunogenic and atherogenic adduct epitopes. Scientific Reports, 2017, 7, 10787.	1.6	23
87	The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. Schizophrenia Bulletin, 2017, 43, 57-63.	2.3	84
88	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	9.4	838
89	Improving Long-Term Outcomes in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2017, 78, e1431.	1.1	2
90	An Individualized Risk Calculator for Research in Prodromal Psychosis. American Journal of Psychiatry, 2016, 173, 980-988.	4.0	458

#	Article	IF	Citations
91	The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. Schizophrenia Research, 2016, 172, 29-34.	1.1	15
92	Traumatic brain injury in individuals at clinical high risk for psychosis. Schizophrenia Research, 2016, 174, 77-81.	1.1	12
93	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophrenia Bulletin, 2016, 42, 1234-1242.	2.3	17
94	Association of Neurocognition With Transition to Psychosis. JAMA Psychiatry, 2016, 73, 1239.	6.0	205
95	Reproducibility and Visual Inspection of Data. Biological Psychiatry, 2016, 80, e33-e35.	0.7	2
96	The Violent Content in Attenuated Psychotic Symptoms. Psychiatry Research, 2016, 242, 61-66.	1.7	14
97	Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. Psychiatry Research - Neuroimaging, 2016, 254, 3-9.	0.9	8
98	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin, 2016, 42, 732-743.	2.3	183
99	Social cognition over time in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research, 2016, 171, 176-181.	1.1	55
100	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. Schizophrenia Research, 2016, 172, 106-113.	1.1	20
101	Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 497-503.	1.6	60
102	At risk or not at risk? A metaâ€analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 2015, 14, 322-332.	4.8	209
103	Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. BMC Psychiatry, 2015, 15, 276.	1.1	18
104	Negative symptoms and impaired social functioning predict later psychosis in <scp>L</scp> atino youth at clinical high risk in the <scp>N</scp> orth <scp>A</scp> merican prodromal longitudinal studies consortium. Microbial Biotechnology, 2015, 9, 467-475.	0.9	26
105	Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion among Clinically High-Risk Youth Developing Psychotic Disorders. Molecular Neuropsychiatry, 2015, 1, 13-22.	3.0	27
106	Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. Psychiatry Research, 2015, 230, 878-884.	1.7	13
107	Theory of mind, emotion recognition and social perception in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research: Cognition, 2015, 2, 133-139.	0.7	46
108	Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. Human Brain Mapping, 2015, 36, 2558-2579.	1.9	63

#	Article	IF	Citations
109	Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. JAMA Psychiatry, 2015, 72, 882.	6.0	284
110	Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2015, 41, 1066-1075.	2.3	71
111	Severity of thought disorder predicts psychosis in persons at clinical high-risk. Schizophrenia Research, 2015, 169, 169-177.	1.1	43
112	Patterns of premorbid functioning in individuals at clinical high risk of psychosis. Schizophrenia Research, 2015, 169, 209-213.	1.1	22
113	Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk. Biological Psychiatry, 2015, 77, 147-157.	0.7	516
114	Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project. Schizophrenia Bulletin, 2015, 41, 419-428.	2.3	195
115	The Relationship of Neurocognition and Negative Symptoms to Social and Role Functioning Over Time in Individuals at Clinical High Risk in the First Phase of the North American Prodrome Longitudinal Study. Schizophrenia Bulletin, 2014, 40, 1452-1461.	2.3	137
116	Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophrenia Research, 2014, 156, 277-280.	1.1	34
117	Functional development in clinical high risk youth: Prediction of schizophrenia versus other psychotic disorders. Psychiatry Research, 2014, 215, 52-60.	1.7	18
118	Stress exposure and sensitivity in the clinical high-risk syndrome: Initial findings from the North American Prodrome Longitudinal Study (NAPLS). Schizophrenia Research, 2014, 160, 104-109.	1.1	66
119	Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis. Schizophrenia Research, 2014, 159, 263-266.	1.1	43
120	Current status specifiers for patients at clinical high risk for psychosis. Schizophrenia Research, 2014, 158, 69-75.	1.1	45
121	The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. Psychiatry Research, 2014, 219, 506-512.	1.7	19
122	Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research, 2014, 218, 39-43.	1.7	13
123	Cortisol Levels and Risk for Psychosis: Initial Findings from the North American Prodrome Longitudinal Study. Biological Psychiatry, 2013, 74, 410-417.	0.7	221
124	Early traumatic experiences in those at clinical high risk for psychosis. Microbial Biotechnology, 2013, 7, 300-305.	0.9	95
125	Theory of mind and social judgments in people at clinical high risk of psychosis. Schizophrenia Research, 2013, 150, 498-504.	1.1	34
126	Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research, 2013, 148, 99-104.	1.1	33

#	Article	IF	CITATIONS
127	North American Prodrome Longitudinal Study (NAPLS 2): Overview and recruitment. Schizophrenia Research, 2012, 142, 77-82.	1.1	235
128	Nuclear and cytoplasmic localization of neural stem cell microRNAs. Rna, 2011, 17, 675-686.	1.6	105
129	Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Microbial Biotechnology, 2010, 4, 220-226.	0.9	48
130	Additional layers of gene regulatory complexity from recently discovered microRNA mechanisms. International Journal of Biochemistry and Cell Biology, 2010, 42, 1236-1242.	1.2	13
131	The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: A naturalistic study of the North American Prodrome Longitudinal Sample. Schizophrenia Research, 2009, 115, 50-57.	1.1	61
132	Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study. Schizophrenia Bulletin, 2009, 35, 894-908.	2.3	368
133	Facial affect recognition in individuals at clinical high risk for psychosis. British Journal of Psychiatry, 2008, 192, 67-68.	1.7	161
134	Assessment of social judgments and complex mental states in the early phases of psychosis. Schizophrenia Research, 2008, 100, 237-241.	1.1	66
135	Prediction of Psychosis in Youth at High Clinical Risk. Archives of General Psychiatry, 2008, 65, 28.	13.8	1,160
136	miRNA and Schizophrenia., 2008,, 267-281.		0
136	miRNA and Schizophrenia., 2008, , 267-281. Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2008, 69, 106-113.	1.1	0
	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia. Schizophreniform Disorder, or Schizoaffective Disorder, Journal of	1.1	
137	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2008, 69, 106-113. North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal		185
137	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2008, 69, 106-113. North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal Schizophrenia Research. Schizophrenia Bulletin, 2007, 33, 665-672.	2.3	185 258
137 138 139	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2008, 69, 106-113. North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal Schizophrenia Research. Schizophrenia Bulletin, 2007, 33, 665-672. Neuroprotection: A New Strategy in the Treatment of Schizophrenia. CNS Spectrums, 2007, 12, 1-16.	2.3	185 258 24
137 138 139	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2008, 69, 106-113. North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal Schizophrenia Research. Schizophrenia Bulletin, 2007, 33, 665-672. Neuroprotection: A New Strategy in the Treatment of Schizophrenia. CNS Spectrums, 2007, 12, 1-16. Early Identification and Treatment of Schizophrenia. CNS Spectrums, 2007, 12, 5-8. Emotion perception and social skill over the course of psychosis: A comparison of individuals "at-riskâ€-for psychosis and individuals with early and chronic schizophrenia spectrum illness.	2.3 0.7 0.7	185 258 24
137 138 139 140	Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2008, 69, 106-113. North American Prodrome Longitudinal Study: A Collaborative Multisite Approach to Prodromal Schizophrenia Research. Schizophrenia Bulletin, 2007, 33, 665-672. Neuroprotection: A New Strategy in the Treatment of Schizophrenia. CNS Spectrums, 2007, 12, 1-16. Early Identification and Treatment of Schizophrenia. CNS Spectrums, 2007, 12, 5-8. Emotion perception and social skill over the course of psychosis: A comparison of individuals "at-riskâ€-for psychosis and individuals with early and chronic schizophrenia spectrum illness. Cognitive Neuropsychiatry, 2007, 12, 198-212. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective	2.3 0.7 0.7	185 258 24 1 172

#	Article	IF	CITATIONS
145	Systematic discovery of the grammar of translational inhibition by RNA hairpins. Journal of Theoretical Biology, 2006, 241, 205-215.	0.8	2
146	What have we learned from CATIE about the pharmacologic treatment of schizophrenia?. Current Psychosis & Therapeutics Reports, 2006, 4, 35-39.	0.1	0
147	Expanding the †central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. Molecular Psychiatry, 2005, 10, 69-78.	4.1	87
148	Evaluating and treating the prodromal stage of schizophrenia. Current Psychosis & Therapeutics Reports, 2005, 3, 79-85.	0.1	0
149	Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis. American Journal of Psychiatry, 2005, 162, 1785-1804.	4.0	1,086
150	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, 2005, 353, 1209-1223.	13.9	5,335
151	Evaluating and treating the prodromal stage of schizophrenia. Current Psychiatry Reports, 2004, 6, 289-295.	2.1	15
152	Brief Evaluation of Medication Influences and Beliefs. Journal of Clinical Psychopharmacology, 2004, 24, 404-409.	0.7	68
153	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry, 2004, 185, 18-24.	1.7	143
154	Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 2004, 161, 1-56.	4.0	1,024
155	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 2003, 54, 453-464.	0.7	194
156	Prodromal Assessment With the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive Validity, Interrater Reliability, and Training to Reliability. Schizophrenia Bulletin, 2003, 29, 703-715.	2.3	1,492
157	Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophrenia Bulletin, 2003, 29, 33-43.	2.3	102
158	Predictors of Noncompliance in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2002, 63, 1121-1128.	1.1	433
159	The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry, 2001, 50, 884-897.	0.7	506
160	Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophrenia Research, 2000, 44, 1-10.	1.1	165
161	Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biological Psychiatry, 2000, 47, 762-766.	0.7	105
162	Markers for Schizophrenia. American Journal of Psychiatry, 2000, 157, 1527-1527.	4.0	2

DIANA O PERKINS

#	Article	IF	CITATIONS
163	The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis. Schizophrenia Bulletin, 1999, 25, 201-222.	2.3	636
164	Personality disorder in HIV infection. International Review of Psychiatry, 1996, 8, 253-258.	1.4	20
165	Longitudinal study of social support and social conflict as predictors of depression and dysphoria among HIVâ€positive and HTVâ€negative gay men. Depression, 1994, 2, 189-199.	0.7	18